...At any rate, the NEJM article describes four bills as having been introduced in the U.S. Congress in 2007 to expedite approval of follow-on protein products. None reached the floor. The article cheerfully concludes "despite failures of the bills... [they] collectively represent important first steps that should help stimulate further discourse... and signal an end to the de facto permanent patent that a recombinant protein therapeutic currently enjoys." In the meantime, its a hard knock life for persons with ultra-rare disorders. (photo credit: dishevld 2007)
Friday, March 21, 2008
Little Orphan Ending
...At any rate, the NEJM article describes four bills as having been introduced in the U.S. Congress in 2007 to expedite approval of follow-on protein products. None reached the floor. The article cheerfully concludes "despite failures of the bills... [they] collectively represent important first steps that should help stimulate further discourse... and signal an end to the de facto permanent patent that a recombinant protein therapeutic currently enjoys." In the meantime, its a hard knock life for persons with ultra-rare disorders. (photo credit: dishevld 2007)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment